Rapport Therapeutics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsRapport Therapeutics is a clinical-stage biotechnology company developing small molecule precision medicines for neurological and psychiatric disorders.
What they do
Rapport Therapeutics uses its RAP technology platform to discover and develop small molecule precision medicines. Its lead program, RAP-219, is in Phase 3 trials for focal onset seizures, with additional development for bipolar mania, long-acting injectable formulation, and primary generalized tonic-clonic seizures. The pipeline also includes RAP-641, an α6β4 nAChR program in chronic pain and migraine.
Revenue drivers
- Product candidates (pre-commercial) — No approved products or revenue; company is pre-revenue.
- Collaborative revenue — $20.0M revenue recorded in Q1 2026; no other quarterly revenue reported.
Recent performance
For Q2 2026, the company reported $0.0M revenue and cash, cash equivalents and short-term investments of $436.1M, excluding restricted cash. Annual net losses widened from $34.8M in 2023 to $78.3M in 2024 and $111.5M in 2025. Operating cash flow was negative $87.5M in 2025. The company expects existing cash to fund operations into the second half of 2029.
Strategy
Management is advancing RAP-219 into pivotal-stage development with FOCUS 1 and FOCUS 2 trials now enrolling. They are expanding the RAP-219 franchise with a Phase 2 bipolar mania trial, a long-acting injectable, and a PGTCS program. The company also continues discovery efforts to build a self-sustaining pipeline. An IND was approved in China for RAP-219 Phase 3 trials, with patient recruitment expected to begin in 4Q 2026.
Risks
- Clinical trial risk — Phase 3 trials may fail to show efficacy or safety, as earlier positive data may not replicate.
- Funding risk — Negative operating cash flow and no approved products mean the company relies on existing cash and future financing to fund operations.
- Regulatory risk — Delays or negative results in the bipolar mania Phase 2 trial or Phase 3 trials could impact ability to obtain regulatory approvals.
- Competitive risk — Other companies may develop competing treatments for epilepsy or other neurological disorders, potentially limiting market opportunity.
Outlook
Topline results for the Phase 2 bipolar mania trial are expected in October 2026. Initial data from the open-label long-term safety trial in FOS are expected in Q4 2026. The company plans to initiate a Phase 3 trial in PGTCS in the first half of 2027. Management expects existing cash to fund operations into the second half of 2029.